Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, helped ignite the current wave of interest in peptide drugs, and it remains one of the best-studied medications in this category.
What It Is
Semaglutide is a synthetic analog of GLP-1, a hormone your gut releases after eating that stimulates insulin secretion, slows gastric emptying, and signals satiety to the brain. Chemical modifications, including a fatty-acid side chain that binds the molecule to albumin in blood, extend its half-life to about a week, versus a few minutes for the natural hormone.
Regulatory Status and Formulations
Semaglutide is FDA-approved in three forms: Ozempic (injectable, for type 2 diabetes, approved 2017), Rybelsus (oral, for type 2 diabetes, approved 2019), and Wegovy (injectable, for chronic weight management, approved 2021). Each required its own dedicated trial program and carries its own approved label.
What the Research Shows
The STEP trial program evaluated semaglutide specifically for weight management, reporting substantial average weight loss among participants compared to placebo over roughly 68 weeks. The later SELECT trial extended this further, evaluating cardiovascular outcomes in people with existing heart disease and overweight or obesity, reporting a reduction in major adverse cardiovascular events, a significant finding that helped support broader clinical and payer interest beyond weight loss alone.
Common Side Effects
As with tirzepatide, gastrointestinal side effects are the most common, and the drug shares a similar boxed warning regarding thyroid C-cell tumors seen in rodent studies, with the same contraindication for those with a personal or family history of medullary thyroid carcinoma or MEN 2.
The Bottom Line
Semaglutide's evidence base is exceptionally deep for a peptide drug, spanning diabetes, weight management, and cardiovascular outcome trials involving tens of thousands of participants combined. That depth of evidence is precisely what separates it, and drugs like it, from research-chemical peptides that share superficial chemical similarities but nothing like the same trial history.
Why Three Different Brand Names Exist
Ozempic, Wegovy, and Rybelsus all contain semaglutide, but each was approved separately for a distinct indication, dose range, and in Rybelsus's case, delivery method. This is a common pattern in pharmaceutical regulation: the same active ingredient can carry multiple brand names and approved uses, each requiring its own dedicated trial evidence, rather than one approval automatically covering every possible use.
Dosing and Administration in Practice
Injectable semaglutide follows a similar gradual titration approach to tirzepatide, starting low and increasing over a period of months to the target maintenance dose, again specifically to manage gastrointestinal tolerability based on trial data. Oral semaglutide (Rybelsus) has its own distinct administration requirements, taken first thing in the morning on an empty stomach with a small amount of plain water, then waiting at least 30 minutes before eating, food, or other medications, since absorption is highly sensitive to stomach contents.